JAZZ Stock Recent News
JAZZ LATEST HEADLINES
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are EVER, JAZZ, PGR, SONY, NWG.
Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
STRL. BATRA and JAZZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 3, 2025.
Stocks like NFG, ENS, TAP and JAZZ are seeing price strength and have a high chance of carrying the momentum forward.
Teaser: STRL, CAPL, BATRA, CYD and JAZZ have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2025.
EME, JAZZ and STRL made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 3, 2025.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise.